KRAS and acute myeloid leukemia: Furthermore, the study conducted by Badar et al. demonstrated that the acquisition of FLT3-ITD and/or RAS (NRAS, KRAS) mutations at the moment of MDS transformation into AML was found in 26% of cases and was associated with extremely poor outcomes with a median survival of 2.4 months [24].